Led by researchers at Beth Israel Deaconess Medical Center (BIDMC), the findings represent the first and largest population-based study to look at cancer treatment for patients with disabilities.
"Because clinical trials typically exclude this population, there is little scientific evidence available to guide doctors in their treatment decisions,"explains the study's lead author Ellen McCarthy, PhD, MPH, of the Division of General Medicine and Primary Care at BIDMC and Assistant Professor of Medicine at Harvard Medical School (HMS). "Consequently, very little is known about cancer treatments for individuals with disabilities."
There are two accepted therapeutic options for early stage breast cancer: mastectomy (removal of the entire breast) and breast-conserving surgery (removal of only the cancer) combined with axillary lymph node dissection and radiation therapy. (Axillary node dissection consists of removal of the lymph nodes to see whether they contain cancer. Radiation therapy consists of daily treatments for approximately six weeks following surgery.) In 1990, the National Institutes of Health (NIH) deemed both treatments equally effective with regard to survival and recurrence of cancer.
However, as the authors describe in their article, "Despite this, studies have repeatedly found that many women with traits that can suggest a social disadvantage – including older age, race or ethnicity, low socioeconomic status [income or education], rural residence and lack of health insurance – do not receive breast-conserving surgery."
Noting that women with disabilities who develop early-stage breast cancer are another "potentially vulnerable group," McCarthy and her coauthors set out to compare the likelihood of receiving initial treatment for early-stage breast cancer between women with and without disabilities, and their survival following diagnosis. They also examined the association between initial treatment and survival in the two groups of women.
Using data from the National Cancer Institute's SEER (Surveillance, Epidemiology, and End Result) tumor registry combined with information from Medicare records, the researchers analyzed a study group consisting of 100,311 women aged 21 to 64 diagnosed with early stage breast cancer during the period between January 1988 and December 1999. Of this group, they determined that 2,800 women were disabled at the time of diagnosis. (Disability was determined based on records documenting the receipt of Social Security Disability Insurance [SSDI] benefits along with Medicare qualifications. Because the Social Security Administration does not release specific information to non-government investigators, the authors were unable to determine the underlying cause of disability.)
After adjusting for demographic and tumor characteristics, the researchers' final analysis found that the women with disabilities were 20 percent less likely to receive breast-conserving surgery compared with women without disabilities. Furthermore, the women with disabilities who did receive breast-conserving surgery were 19 percent less likely to receive lymph node dissection and 17 percent less likely to receive radiation therapy following their surgery – both considered part of the standard treatment protocol – than were the other women. The findings also showed that women with disabilities had a 29 percent higher risk of dying from their breast cancer but, says McCarthy, the differences in initial treatment did not explain the survival disadvantage among women with disabilities.
"The explanation for our findings is multi-factorial," explains senior author Lisa Iezzoni, MD, MSc, Professor of Medicine at HMS, who has studied health care issues as they apply to disabled individuals for more than 10 years and at the time of the study served as Co-Director of Research in BIDMC's Division of Primary Care and General Medicine.
"Among some women with disabilities, there may be a greater possibility for complications [arising from the treatment] due to their physical conditions [which could account for the higher mortality rate.] Their physicians may be less likely to offer them the less invasive option of breast-conserving surgery, assuming that physical appearance is not important to them [accounting for higher rates of mastectomy rather than breast-conserving surgery].
"And logistical issues could also be playing a role," she adds. "The women with disabilities may, for example, be unable to arrange for daily transportation to and from radiation therapy treatments, or, in the case of disabled patients with movement disorders, their conditions might make it physically difficult for them to undergo required radiation treatments."
Among these various findings, notes McCarthy, the lack of radiation therapy for the women with disabilities who underwent breast-conserving surgery is of particular concern.
"Our research shows that these women were not receiving standard post-surgical therapy including adjuvant radiation therapy," she says. "This means that they are at higher risk that their cancer will come back and they could potentially experience greater rates of cancer-related morbidity."
The authors recommend that future research focus on the potential reasons for these lower radiotherapy rates, including the extent to which the disparities reflect patients' preferences for treatment, patient-physician communication, inadequate access, and other barriers to care,such as transportation.
"Because this is such a large study, we hope it will serve as a starting point for understanding what is happening [among disabled populations] when it comes to cancer treatment," explains McCarthy. "These findings tell us that there are indeed differences in treatment decisions, but do not tell us the reasons for these differences."
Concludes Iezzoni, "We need to be vigilant when a woman with a disability has breast cancer. We need to better understand how she views her treatment choices given her physical, social and life context and we need to make sure that she has the best information available to make treatment decisions for herself."
Bonnie Prescott | EurekAlert!
Researchers release the brakes on the immune system
18.10.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn
Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine
University of Maryland researchers contribute to historic detection of gravitational waves and light created by event
On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...
Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.
Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....
Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).
When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...
Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.
How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...
Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.
It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...
17.10.2017 | Event News
10.10.2017 | Event News
10.10.2017 | Event News
20.10.2017 | Information Technology
20.10.2017 | Materials Sciences
20.10.2017 | Interdisciplinary Research